The management of hypertrophic cardiomyopathy

New England Journal of Medicine

Volumn 336, Issue 11, 1997, Pages 775-785

  Spirito, Paolo ^a   Seidman, Christine E ^b   McKenna, William J ^c   Maron, Barry J ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DISOPYRAMIDE; VERAPAMIL;

CLINICAL EXAMINATION; DEFIBRILLATOR; GENETIC RISK; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART OUTFLOW TRACT OBSTRUCTION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYNCOPE;

ADRENERGIC BETA-ANTAGONISTS; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; HUMANS; RISK FACTORS; VENTRICULAR OUTFLOW OBSTRUCTION; VERAPAMIL;

EID: 0031052480     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199703133361107     Document Type: Review

References (151)

1. Frank S, Braunwald E. Idiopathic hypertrophic subaortic stenosis: clinical analysis of 126 patients with emphasis on the natural history. Circulation 1968;37:759-88.
2. Goodwin JF. Congestive and hypertrophic cardiomyopathies: a decade of study. Lancet 1970;1:732-9.
3. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy: the importance of the site and the extent of hypertrophy: a review. Prog Cardiovasc Dis 1985;28:1-83.
4. Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med 1986;315:610-4.
5. Maron BJ, Bonow RO, Cannon RO III, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med 1987;316:780-9, 844-52.
6. Spirito P, Chiarella F, Carratino I, Berisso MZ, Bellorti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an out-patient population. N Engl J Med 1989;320:749-55.
7. Louie EK, Edwards LC III. Hypertrophic cardiomyopathy. Prog Cardiovasc Dis 1994;36:275-308.
8. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 1995;92:1680-92.
9. Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980;303:322-4.
10. Powell AC, Fuchs P, Finkelstein DM, et al. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation 1993;88:1083-92.
11. Nunain SO, Roelke M, Trouton T, et al. Limitations and late complications of third-generation automatic cardioverter-defibrillators. Circulation 1995;91:2204-13.
12. Zipes DP Are implantable cardioverter-defibrillators better than conventional antiarrhythmic drugs for survivors of cardiac arrest? Circulation 1995;91:2115-7.
13. Hassenstein P, Storch HH, Schmitz W. Erfahrungen mit der Schrittmacherdauerbehandlung bei Patienten mit obstrucktiver Kardiomyopathie. Thoraxchirurgie 1975;23:496-8.
14. Duck H-J, Hutschenreiter W, Pankau H, Trenckmann H. Vorhofsynchrone Ventrikelstimulation mit vetkürzter a.v. Verzögerungszeit als Therapieprinzip der hypertrophischen obstruktiven Kardiomyopathic. Z Gesamte Inn Med Ihre Grenzgebiete 1984;39:437-47.
15. McDonald K, McWilliams E, O'Keeffe B, Maurer B. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. Eur Heart J 1988;9:893-8.
16. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet 1992;339:1318-23.
17. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994;90:2731-42.
18. Slade AKB, Sadoul N, Shapiro L, et al. DDD Pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart 1996;75:44-9.
19. Watkins H, Rosenzweig A, Hwang D-S, et al. Characteristics and prognostic implications of myosin rnissense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992;326:1108-14.
20. Schwartz K, Carrier L, Guicheney P, Komajda M. Molecular basis of familial cardiomyopathies. Circulation 1995;91:532-40.
21. Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 1995;92:1336-47.
22. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995;332:1058-64.
23. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation 1995;92:785-9.
24. Shapiro LM, Zezulka A. Hypertrophic cardiomyopathy: a common disease with a good prognosis: five year experience of a district general hospital. Br Heart J 1983;50:530-3.
25. Kofflard MJ, Waldstein DJ, Vos J, ten Cate FJ. Prognosis in hypertrophic cardiomyopathy observed in a large clinic population. Am J Cardiol 1993;72:939-43.
26. Maron BJ, Spirito P. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. Am J Cardiol 1993;72:970-2.
27. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994;90:2743-7.
28. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995;26:1529-36.
29. Cannan CR, Reeder GS, Bailey KR, Melton LJ III, Gersh BJ. Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990. Circulation 1995;92:2488-95.
30. Maron BJ, Henry WL, Clark CE, Redwood DR, Roberts WC, Epstein SE. Asymmetric septal hypertrophy in childhood. Circulation 1976;53:9-19.
31. Fiddler GI, Tajik AJ, Weidman WH, McGoon DC, Ritter DG, Giuliani ER. Idiopathic hypertrophic subaortic stenosis in the young. Am J Cardiol 1978;42:793-9.
32. McKenna WJ, Deanfield J, Faruqui A, England D, Oakley CM, Goodwin JF. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;47: 532-8.
33. Seidman CE, Seidman JG. Gene mutations that cause familial hypertrophic cardiomyopathy. In: Haber E, ed. Molecular cardiovascular medicine. New York: Scientific American, 1995:193-209.
34. Thierfelder L, Watkins H, MacRae C, et al. α-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994;77:701-12.
35. Watkins H, Anan R, Coviello DA, Spirito P, Seidman JG, Seidman CE. A de novo mutation in α-tropomyosin that causes hypertrophic cardiomyopathy. Circulation 1995;91:2302-5.
36. Watkins H, Conner D, Thierfelder L, et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995;11:434-7.
37. Bonne G, Carrier L, Bercovici I, et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet 1995;11:438-40.
38. Poetter K, Jiang H, Hassanzadeh S, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 1996;13:63-9.
39. MacRae CA, Ghaisas N, Kass S, et al. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest 1995;96:1216-20.
40. Stewart S, Mason DT, Braunwald E. Impaired rate of left ventricular filling in idiopathic hypertrophic subaortic stenosis and valvular aortic stenosis. Circulation 1968;37:8-14.
41. Sanderson JE, Gibson DG, Brown DJ, Goodwin JF. Left ventricular filling in hypertrophic cardiomyopathy: an angiographic study. Br Heart J 1977;39:661-70.
42. Spirito P, Maron BJ, Chiarella F, et al. Diastolic abnormalities in patients with hypertrophic cardiomyopathy: relation to magnitude of left ventricular hypertrophy. Circulation 1985;72:310-6.
43. Spirito P, Maron BJ, Bonow RO, Epstein SE. Severe functional limitation in patients with hypertrophic cardiomyopathy and only mild localized left ventricular hypertrophy. J Am Coll Cardiol 1986;8:537-44.
44. Nihoyannopoulos P, Karatasakis G, Frenneaux M, McKenna WJ, Oakley CM. Diastolic function in hypertrophic cardiomyopathy: relation to exercise capacity. J Am Coll Cardiol 1992;19:536-40.
45. Thompson DS, Naqvi N, Juul SM, et al. Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy. Br Heart J 1980;44:488-98.
46. Pasternac A, Noble J, Streulens U, Elie R, Henschke C, Bourassa MG. Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation 1982;65:778-89.
47. Cannon RO III, Rosing DR, Maron BJ, et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 1985;71:234-43.
48. O'Gara PT, Bonow RO, Maron BJ, et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation 1987;76:1214-23.
49. Cannon RO III, Dilsizian V, O'Gara PT, et al. Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation 1991;83: 1660-7.
50. Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol 1979;43:1086-102.
51. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;8:545-57.
52. Harrison DC, Braunwald E, Glick G, Mason DT, Chidsey CA, Ross J Jr. Effects of beta adrenergic blockade on the circulation, with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 1964;29:84-98.
53. Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation 1967;35:847-51.
54. Flamm MD, Harrison DC, Hancock EW. Muscular subaortic stenosis: prevention of outflow obstruction with propranolol. Circulation 1968;38: 846-58.
55. Rosing DR, Kent KM, Maron BJ, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation 1979;60:1208-13.
56. Hanrath P, Mathey DG, Kremer P, Sonntag F, Bleifeld W. Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy. Am J Cardiol 1980;45: 1258-64.
57. Bonow RO, Rosing DR, Bacharach SL, et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation 1981;64:787-96.
58. ten Gate FJ, Serruys PW, Mey S, Roelandt J. Effects of short-term administration of verapamil on left ventricular relaxation and filling dynamics measured by a combined hemodynamic-ultrasonic technique in patients with hypertrophic cardiomyopathy. Circulation 1983;68:1274-9.
59. Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short-and long-term effects. Circulation 1985;72:853-64.
60. Hess OM, Murakami T, Krayenbuehl HP. Does verapamil improve left ventricular relaxation in patients with myocardial hypertrophy? Circulation 1986;74:530-43.
61. Udelson JE, Bonow RO, O'Gara PT, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989;79:1052-60.
62. Lorell BH, Paulus WJ, Grossman W, Wynne J, Cohn PF. Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy. Circulation 1982;65:499-507.
63. Iwase M, Sotobata I, Takagi S, Miyaguchi K, Jing HX, Yokota M. Effects of diltiazem on left ventricular diastolic behavior in patients with hypertrophic cardiomyopathy: evaluation with exercise pulsed Doppler echo-cardiography. J Am Coll Cardiol 1987;9:1099-105.
64. Betocchi S, Piscione F, Losi MA, et al. Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy. Am J Cardiol 1996;78:451-7.
65. Betocchi S, Cannon RO III, Watson RM, et al. Effects of sublingual nifedipine on hemodynamics and systolic and diastolic function in patients with hypertrophic cardiomyopathy. Circulation 1985;72:1001-7.
66. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med 1982;307:997-9.
67. Frenneaux MP, Porter A, Caforio ALP, Odawara H, Counihan PJ, McKenna WJ. Determinants of exercise capacity in hypertrophic cardiomyopathy. J Am Coll Cardiol 1989;13:1521-6.
68. Gilligan DM, Chan WL, Joshi J, et al. A double-blind, placebo controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;21:1672-9.
69. Gilligan DM, Chan WL, Stewart RA, Oakley CM. Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy. Am J Cardiol 1991;68:766-72.
70. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981;64:437-41.
71. Gilligan DM, Chan WL, Stewart RA, Joshi J, Nihoyannopoulos P, Oakley CM. Cardiac responses assessed by echocardiography to changes in preload in hypertrophic cardiomyopathy. Am J Cardiol 1994;73:312-5.
72. Lever HM, Karam RF, Currie PJ, Healy BP. Hypertrophic cardiomyopathy in the elderly: distinctions from the young based on cardiac shape. Circulation 1989;79:580-9.
73. Lewis JF, Maron BJ. Elderly patients with hypertrophic cardiomyopathy: a subset with distinctive left ventricular morphology and progressive clinical course late in life. J Am Coll Cardiol 1989;13:36-45.
74. Fay WP, Taliercio CP, Ilstrup DM, Tajik AJ, Gersh BJ. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 1990; 16:821-6.
75. Louie EK, Maron BJ. Hypertrophic cardiomyopathy with extreme increase in left ventricular wall thickness: functional and morphologic features and clinical significance. J Am Coll Cardiol 1986;8:57-65.
76. Maron BJ, Gross BJ, Stark SI. Extreme left ventricular hypertrophy. Circulation 1995;92:2748.
77. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990;15:1279-85.
78. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley CM, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. I. Influence on prognosis. Br Heart J 1981;46:168-72.
79. Furlan AJ, Craciun AR, Raju NR, Hart N. Cerebrovascular complications associated with idiopathic hypertrophic subaortic stenosis. Stroke 1984;15:282-4.
80. Spirito P, Lakatos E, Maron BJ. Degree of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy and chronic atrial fibrillation. Am J Cardiol 1992;69:1217-22.
81. McKenna WJ, Harris L, Rowland E, et al. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol 1984;54:802-10.
82. Gosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267:3289-93.
83. Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals: from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996;93:1262-77.
84. Spirito P, Maron BJ. Absence of progression of left ventricular hypertrophy in adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1987;9:1013-7.
85. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987;60:123-9.
86. Shirani J, Maron BJ, Cannon RO III, Shahin S, Roberts WC. Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation. Am J Cardiol 1993;72:434-40.
87. Morrow AG, Reitz BA, Epstein SE, et al. Operative treatment in hypertrophic subaortic stenosis: techniques, and the results of pre and post-operative assessments in 83 patients. Circulation 1975;52:88-102.
88. Maron BJ, Merrill WH, Freier PA, Kent KM, Epstein SE, Morrow AG. Long-term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis. Circulation 1978;57:1205-13.
89. Williams WG, Wigle ED, Rakowski H, Smallhorn J, LeBlanc J, Trusler GA. Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation 1987;76:Suppl V:V-104-V-108.
90. McIntosh CL, Maron BJ. Current operative treatment of obstructive hypertrophic cardiomyopathy. Circulation 1988;78:487-95.
91. Cohn LH, Trehan H, Collins JJ Jr. Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 1992;70:657-60.
92. Schulte HD, Bircks WH, Loesse B, Godehardt EA, Schwartzkopff B. Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic myectomy: late results up to twenty-five years. J Thorac Cardiovasc Surg 1993;106:709-17.
93. ten Berg JM, Suttorp MJ, Knaepen PJ, Ernst SM, Vermeulen FE, Jaarsma W. Hypertrophic obstructive cardiomyopathy: initial results and long-term follow-up after Morrow septal myectomy. Circulation 1994;90: 1781-5.
94. Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM. Surgical management of hypertrophic obstructive cardiomyopathy: early and late results. J Thorac Cardiovasc Surg 1995;110:195-208.
95. Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 1996;111:586-94.
96. McCully RB, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996;94:467-71.
97. Cooley DA, Leachman RD, Hallman GL, Gerami S, Hall RJ. Idiopathic hypertrophic subaortic stenosis: surgical treatment including mitral valve replacement. Arch Surg 1971;103:606-9.
98. McIntosh CL, Greenberg GJ, Maron BJ, Leon MB, Cannon RO III, Clark RE. Clinical and hemodynamic results after mitral valve replacement in patients with obstructive hypertrophic cardiomyopathy. Ann Thorac Surg 1989;47:236-46.
99. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy: significance of producing left ventricular outflow obstruction. Circulation 1991;84:1188-97.
100. McIntosh CL, Maron BJ, Cannon RO III, Klues HG. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Circulation 1992;86:Suppl II:II-60-11-67.
101. Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 1995;92:Suppl II:II-122-II-127.
102. Kofflard MJ, van Herwerden LA, Waldstein DJ, et al. Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 1996; 28:197-202.
103. Cooper MM, McIntosh CL, Tucker E, Clark RE. Operation for hypertrophic subaortic stenosis in the aged. Ann Thorac Surg 1987;44:370-8.
104. Siegman IL, Maron BJ, Permut LC, McIntosh CL, Clark RE. Results of operation for coexistent obstructive hypertrophic cardiomyopathy and coronary artery disease. J Am Coll Cardiol 1989;13:1527-33.
105. Marwick TH, Stewart WJ, Lever HM, et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. J Am Coll Cardiol 1992;20:1066-72.
106. Grigg LE, Wigle ED, Williams WD, Daniel LB, Rakowski H. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol 1992;20:42-52.
107. Shah PM, Gramiak R, Adelman AG, Wigle ED. Echocardiographic assessment of the effects of surgery and propranolol on the dynamics of outflow obstruction in hypertrophic subaortic stenosis. Circulation 1972; 45:516-21.
108. Henry WL, Clark CE, Griffith JM, Epstein SE. Mechanism of left ventricular outflow obstruction in patients with obstructive asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis). Am J Cardiol 1975;35:337-45.
109. Schapira JN, Stemple DR, Martin RP, Rakowski H, Stinson EB, Popp RL. Single and two-dimensional echocardiographic visualization of the effects of septal myectomy in idiopathic hypertrophic subaortic stenosis. Circulation 1978;58:850-60.
110. Spirito P, Maron BJ. Significance of left ventricular outflow tract cross-sectional area in hypertrophic cardiomyopathy: a two-dimensional echocardiographic assessment. Circulation 1983;67:1100-8.
111. Spirito P, Maron BJ, Rosing DR. Morphologic determinants of hemodynamic state after ventricular septal myotomy-myectomy in patients with obstructive hypertrophic cardiomyopathy: M mode and two-dimensional echocardiographic assessment. Circulation 1984;70:984-95.
112. Cannon RO III, McIntosh CL, Schenke WH, Maron BJ, Bonow RO, Epstein SE. Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy. Circulation 1989;79:766-75.
113. Cannon RO III, Dilsizian V, O'Gara PT, et al. Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy. Circulation 1992;85:1039-45.
114. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic obstructive cardiomyopathy: a randomized, double-blind, crossover study. J Am Coll Cardiol 1997;29:435-41.
115. Nishimura RA, Hayes DL, Ilstrup DM, Holmes DR, Tajik AJ. Effects of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy: acute Doppler echocardiographic and catheterization hemodynamic study. J Am Coll Cardiol 1996;27:421-30.
116. Betocchi S, Losi MA, Piscione F, et al. Effects of dual-chamber pacing in hypertrophic cardiomyopathy on left ventricular outflow tract obstruction and on diastolic function. Am J Cardiol 1996;77:498-502.
117. Spirito P, McKenna WJ, Schultheiss HP. DDD Pacing in obstructive HCM. Circulation 1995;92:1670-3.
118. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-4.
119. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982;65:1388-94.
120. DeRose JJ Jr, Banas JS Jr, Winters SL. Current perspectives on sudden cardiac death in hypertrophic cardiomyopathy. Prog Cardiovasc Dis 1994;36:475-84.
121. McKenna WJ, Chetty S, Oakley CM, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy: exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. Am J Cardiol 1980;45:1-5.
122. Canedo MI, Frank MJ, Abdulla AM. Rhythm disturbances in hypertrophic cardiomyopathy: prevalence, relation to symptoms and management. Am J Cardiol 1980;45:848-55.
123. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981;48:252-7.
124. Nicod P, Polikar R, Peterson KL. Hypertrophic cardiomyopathy and sudden death. N Engl J Med 1988;318:1255-7.
125. McKenna WJ, Franklin RC, Nihoyannopoulos P, Robinson KC, Dean-field JE. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988;11:147-53.
126. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux M, McKenna WJ. Prospective diagnostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation (in press).
127. Joseph S, Balcon R, McDonald L. Syncope in hypertrophic obstructive cardiomyopathy due to asystole. Br Heart J 1972;34:974-6.
128. Chmielewzki CA, Riley RS, Mahendran A, Most AS. Complete heart block as a cause of syncope in asymmetric septal hypertrophy. Am Heart J 1977;93:91-3.
129. Gilligan DM, Nihoyannopoulos P, Chan WL, Oakley CM. Investigation of a hemodynamic basis for syncope in hypertrophic cardiomyopathy: use of a head-up tilt test. Circulation 1992;85:2140-8.
130. Maron BJ, Lipson LC, Roberts WC, Savage DD, Epstein SE. "Malignant" hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death. Am J Cardiol 1978;41: 1133-40.
131. Saumarez RC, Slade AKB, Grace AA, Sadoul N, Camm AJ, McKenna WJ. The significance of paced electrogram fractionation in hypertrophic cardiomyopathy: a prospective study. Circulation 1995;91:2762-8.
132. Spirito P, Watson RM, Maron BJ. Relation between extent of left ventricular hypertrophy and occurrence of ventricular tachycardia in hypertrophic cardiomyopathy. Am J Cardiol 1987;60:1137-42.
133. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990;15:1521-6.
134. Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med 1991;324:295-301.
135. Maron BJ, Isner JM, McKenna WJ. Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol 1994;24: 880-5.
136. Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes: insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995;91:1596-601.
137. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes: clinical, demographic, and pathological profiles. JAMA 1996;276:199-204.
138. Geibel A, Brugada P, Zehender M, Stevenson W, Waldecker B, Wellens HJ. Value of programmed electrical stimulation using a standardized ventricular stimulation protocol in hypertrophic cardiomyopathy. Am J Cardiol 1987;60:738-9.
139. Kuck K-H, Kunze KP, Schluter M, Nienaber CA, Costard A. Programmed electrical stimulation in hypertrophic cardiomyopathy: results in patients with and without cardiac arrest or syncope. Eur Heart J 1988;9: 177-85.
140. Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy: prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992;86:730-40.
141. Wellens HJ, Brugada P, Stevenson WG. Programmed electrical stimulation of the heart in patients with life-threatening arrhythmias: what is the significance of induced arrhythmias and what is the correct stimulation protocol? Circulation 1985;72:1-7.
142. McKenna W, Harris L, Deanfield J. Syncope in hypertrophic cardiomyopathy. Br Heart J 1982;47:177-9.
143. Nienaber CA, Hiller S, Spielmann RP, Geiger M, Kuck KH. Syncope in hypertrophic cardiomyopathy: multivariate analysis of prognostic determinants. J Am Coll Cardiol 1990;15:948-55.
144. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;22:796-804.
145. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and age in hypertrophic cardiomyopathy. J Am Coll Cardiol 1989;13:820-3.
146. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056-62.
147. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol 1993;72:280-7.
148. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321: 406-12.
149. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985;53:412-6.
150. Fananapazir L, Leon MB, Bonow RO, Tracy CM, Cannon RO III, Epstein SE. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991;67:169-74.
151. Harris L, McKenna WJ, Rowland E, Holt DW, Storey GCA, Krikler DM. Side effects of long-term amiodarone therapy. Circulation 1983;67: 45-51.